Zura Bio (Zura Bio) Long-Term Debt : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Zura Bio Long-Term Debt?

Zura Bio's Long-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.

Zura Bio Long-Term Debt Historical Data

The historical data trend for Zura Bio's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio Long-Term Debt Chart

Zura Bio Annual Data

Trend

Dec21

Mar22

Dec23

Long-Term Debt

Zura Bio Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial					-	-	-	-	-

Zura Bio (NAS:ZURA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Zura Bio Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Zura Bio's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zura Bio (Zura Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

94E:Germany

Address

4225 Executive Square, Suite 600, La Jolla, CA, USA, 92037

Website

https://www.zurabio.com

Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.

Executives

Parvinder Thiara	director, 10 percent owner	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Amit Munshi	director	C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Graham Neil Murray Hamilton	director	33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Sandeep Chidambar Kulkarni	director	92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Kimberly Ann Davis	officer: Secretary and General Counsel	C/O ZURA BIO INC., 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Gary Whale	officer: EVP and CTO	2 THE BEACHES, SHIPLAKE, HENLEY-ON-THAMES, OXFORDSHIRE X0 RG9 3BT
Theresa Lowry	officer: EVP and CHRO	3629 VILLA TERRACE, SAN DIEGO CA 92104
Michael Howell	officer: SVP, Translational Medicine	4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Hana Immunotherapeutics Llc	10 percent owner	6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Chris Kim	10 percent owner	6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Ewon Comfortech Co., Ltd.	10 percent owner	8, CHEOMDAN 1-RO, JEONGUP-SI, JEONLABUK-DO M5 320836
Steven J Schoch	director	2748 BUSH STREET, SAN FRANCISCO CA 94115
Preston Klassen	officer: President and COO	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Christopher Cabell	officer: EVP and CMO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jennifer Jarrett	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105